Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124617093 | 12461709 | 3 | F | 20160707 | 20160613 | 20160707 | EXP | CA-PFIZER INC-2016288429 | PFIZER | 57.00 | YR | M | Y | 0.00000 | 20160707 | CN | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124617093 | 12461709 | 1 | SS | ENBREL | ETANERCEPT | 1 | Subcutaneous | 50 MG, WEEKLY | N | 0 | 50 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | /wk | |||||
| 124617093 | 12461709 | 2 | PS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Intramuscular | 25 MG, WEEKLY | N | 11719 | 25 | MG | SOLUTION FOR INJECTION | /wk | |||||
| 124617093 | 12461709 | 3 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Subcutaneous | 25 MG, WEEKLY | N | 11719 | 25 | MG | SOLUTION FOR INJECTION | /wk | |||||
| 124617093 | 12461709 | 4 | SS | SULFASALAZINE. | SULFASALAZINE | 1 | Oral | 2 G, DAILY | N | 7073 | 2 | G | |||||||
| 124617093 | 12461709 | 5 | SS | ARTHROTEC | DICLOFENAC SODIUMMISOPROSTOL | 1 | Oral | 50 MG, TWICE A DAY | 20607 | 50 | MG | TABLET | BID | ||||||
| 124617093 | 12461709 | 6 | SS | PLAQUENIL | HYDROXYCHLOROQUINE SULFATE | 1 | 400 MG, DAILY | N | 0 | 400 | MG | ||||||||
| 124617093 | 12461709 | 7 | SS | HUMIRA | ADALIMUMAB | 1 | Subcutaneous | 40 MG, EVERY TWO WEEKS | N | 0 | 40 | MG | |||||||
| 124617093 | 12461709 | 8 | SS | SIMPONI | GOLIMUMAB | 1 | Subcutaneous | 50 MG, EVERY 3 WEEKS | N | 0 | 50 | MG | Q3W | ||||||
| 124617093 | 12461709 | 9 | SS | ORENCIA | ABATACEPT | 1 | Subcutaneous | 125 MG, WEEKLY | N | 0 | 125 | MG | /wk | ||||||
| 124617093 | 12461709 | 10 | SS | LEFLUNOMIDE. | LEFLUNOMIDE | 1 | UNK | N | 0 | ||||||||||
| 124617093 | 12461709 | 11 | SS | GOLD (198 AU) | GOLD | 1 | UNK | N | 0 | INJECTION | |||||||||
| 124617093 | 12461709 | 12 | C | ADVIL | IBUPROFEN | 1 | Oral | 200 MG, ONCE A DAY IF NEEDED | 0 | 200 | MG | ||||||||
| 124617093 | 12461709 | 13 | C | TYLENOL | ACETAMINOPHEN | 1 | 650 MG, TWICE A DAY IF NEEDED | 0 | 650 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124617093 | 12461709 | 1 | Rheumatoid arthritis |
| 124617093 | 12461709 | 2 | Rheumatoid arthritis |
| 124617093 | 12461709 | 4 | Rheumatoid arthritis |
| 124617093 | 12461709 | 5 | Rheumatoid arthritis |
| 124617093 | 12461709 | 6 | Rheumatoid arthritis |
| 124617093 | 12461709 | 7 | Rheumatoid arthritis |
| 124617093 | 12461709 | 8 | Rheumatoid arthritis |
| 124617093 | 12461709 | 9 | Rheumatoid arthritis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124617093 | 12461709 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124617093 | 12461709 | Alopecia | |
| 124617093 | 12461709 | Drug ineffective | |
| 124617093 | 12461709 | Nausea | |
| 124617093 | 12461709 | Rheumatoid arthritis | |
| 124617093 | 12461709 | Treatment failure |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124617093 | 12461709 | 8 | 201507 | 0 |